Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China
| Autor: | Jing-Wen Wang, Yonghui Li, Li Yu, Xiao-Ning Gao, Quan-Shun Wang, Jian-Liang Shen, Xiaoyan Ke, Heng-Xiang Wang, Feng Liu, Jianmin Luo, Hui Liu, Hong-Hua Li, Liang-Ding Hu, Mei-Yun Fang, Zhao Wang, Li-Ping Dou, Dan Gong, Yu Jing, Qing-Ming Yang, Yi-Gai Ma, Hui-Ren Chen, Wei Li |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Adult medicine.medical_specialty China Myeloid MEDLINE Consolidation therapy 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Clinical efficacy Retrospective Studies business.industry Remission Induction Cytarabine Myeloid leukemia Retrospective cohort study Hematology General Medicine medicine.disease Leukemia Leukemia Myeloid Acute medicine.anatomical_structure Treatment Outcome 030220 oncology & carcinogenesis business 030215 immunology medicine.drug |
| Zdroj: | Acta haematologica. 136(4) |
| ISSN: | 1421-9662 |
| Popis: | Background: The survival of patients with acute myeloid leukemia (AML) with t(8;21) was reported to be shorter in China than in other countries. Patients: We analyzed the correlation between different cytarabine (Ara-c) regimens and outcome in 255 t(8;21) AML patients in China who received postremission consolidation chemotherapy only. Results: The 5-year overall survival (OS) of the high-dose Ara-c group (HDAC; 2≤ Ara-c ≤3 g/m2), intermediate-dose Ara-c group (MDAC; 1.0≤ Ara-c 2), low-dose Ara-c group (LDAC; 0.2< Ara-c 2) and standard-dose Ara-c group (SDAC; 0.1≤ Ara-c ≤0.2 g/m2) were 65.3, 39.4, 25.2 and 27.9%, respectively (p = 0.003). In the HDAC group, but not in the MDAC group, the 5-year OS of patients who achieved 3-4 cycles of chemotherapy was superior to those who underwent 1-2 cycles (84.4 vs. 43.6%, p < 0.05), and the 3-year OS of patients who achieved an accumulated 36 g/m2 of Ara-c was significantly higher compared to those who did not (85.3 vs. 39.2%, p < 0.05). Multivariate analysis indicated that factors such as WBC >3.5 × 109/l, PLT ≤30 × 109/l, and extramedullary infiltration were associated with a poor prognosis. Conclusion: The survival of t(8;21) AML patients treated with high-dose Ara-c (≥2 g/m2) was superior to other dose levels in postremission consolidation chemotherapy. Patient survival was improved by 3-4 cycles of chemotherapy with an accumulated concentration of 36 g/m2 of Ara-c. WBC >3.5 × 109/l, PLT ≤30 × 109/l and extramedullary infiltration could be indicative of a poor clinical prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|